Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes

Background Glycated hemoglobin (HbA1c) is accepted as the most reliable marker for assessing chronic glycemia. The present study aimed to investigate glycemic control in cardiovascular outcome trials (CVOTs) performed by pharmaceutical sponsors, at the request of the United States Food and Drug Admi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Rumiko Shimazawa, Masayuki Ikeda
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2019-12-01
coleção:	Journal of Pharmaceutical Policy and Practice
Assuntos:	bias cardiovascular diseases clinical trials drug approval glycated hemoglobin hypoglycemic agents type 2 diabetes mellitus
Acesso em linha:	http://dx.doi.org/10.1186/s40545-019-0193-y
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!